Finding new ways to improve immunotherapy for melanoma patients
A novel pathway to overcome resistance to immunotherapy in melanoma
This study is looking at how to make immunotherapy work better for melanoma patients who haven't responded well or have come back after treatment by focusing on a protein called ULK1, which helps control the immune system.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10976865 on NIH RePORTER |
What this research studies
This research investigates how to enhance the effectiveness of immunotherapy in melanoma patients who either do not respond to treatment or relapse after initial success. The team focuses on a specific protein, ULK1, which plays a role in regulating immune responses. By inhibiting ULK1, they aim to reduce the expression of genes that suppress the immune system while maintaining those that stimulate it, potentially leading to better treatment outcomes. The research involves both laboratory experiments and studies in melanoma models to validate their findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are melanoma patients who have experienced resistance to immunotherapy or have relapsed after initial treatment.
Not a fit: Patients with early-stage melanoma or those who have not undergone immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy responses for melanoma patients, increasing survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in targeting similar pathways to enhance immunotherapy, indicating potential for success in this novel approach.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Nora Vaz Saleiro, Diana — Northwestern University at Chicago
- Study coordinator: Nora Vaz Saleiro, Diana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.